No results for ‘’
TTK Healthcare Ltd
₹1115.40
(1.67%)
Thu, 17 Sept 2026, 05:34 pm
Health Technology
Pharmaceuticals: Major
24.5KTTK Healthcare Ratios
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 28.98 | 20.38 | 4.72 | 9.81 | 21.95 | 21.30 | 19.42 | 22.10 | 32.82 | 44.71 | 31.69 | 32.85 | 81.83 | 39.34 | 37.50 | 15.05 | 28.17 | 2.28 | 33.35 | 20.71 |
| Price to book ratio | 1.59 | 1.38 | 1 | 1.24 | 3.08 | 4.16 | 3.46 | 3.20 | 3.80 | 6.11 | 5.27 | 3.91 | 6.38 | 3.81 | 1.86 | 2.37 | 3.55 | 1.53 | 2.09 | 1.59 |
| Price to sales ratio | 0.31 | 0.29 | 0.29 | 0.35 | 0.79 | 1.01 | 0.86 | 0.82 | 0.98 | 1.50 | 1.40 | 1.17 | 2.57 | 1.53 | 0.72 | 1.47 | 1.96 | 2.01 | 2.78 | 2.11 |
| Price to cash flow ratio | 6.90 | 123.62 | 8.76 | 6.93 | 11.58 | 13.23 | 78.69 | 14.31 | 41.38 | 20.09 | 21.04 | 31.99 | 53.17 | 44.81 | 18.57 | 6.23 | 21.34 | 0 | 42.26 | 29.32 |
| Enterprise value | 56.95Cr | 48.94Cr | 20.96Cr | 42.15Cr | 165Cr | 265Cr | 253Cr | 252Cr | 354Cr | 686Cr | 670Cr | 556Cr | 1397Cr | 862Cr | 360Cr | 490Cr | 920Cr | 641Cr | 1273Cr | 860Cr |
| Enterprise value to EBITDA ratio | 8.55 | 7.14 | 3.69 | 3.73 | 10.52 | 12.31 | 10.53 | 12.31 | 18.24 | 23.12 | 18.38 | 14.24 | 32.66 | 16.92 | 12.21 | 24.44 | 40.15 | 19.86 | 32.90 | 23.89 |
| Debt to equity ratio | 0.37 | 0.29 | 0.23 | 0.24 | 0.22 | 0.16 | 0.21 | 0.23 | 0.29 | 0.35 | 0.28 | 0.15 | 0.20 | 0.11 | 0.12 | 0.06 | 0.07 | 0.03 | 0.02 | 0.02 |
| Return on equity % | 0 | 7.10 | 23.14 | 13.19 | 14.40 | 21.02 | 19.16 | 15.28 | 12.08 | 14.35 | 17.81 | 12.76 | 9.47 | 10.06 | 4.92 | 13.53 | 5.93 | 6.96 | 6.43 | 7.90 |
TTK Healthcare Ltd Ratios
The TTK Healthcare Ltd Ratios page provides a complete fundamental analysis of TTK Healthcare Ltd using key valuation, profitability, and financial strength metrics. Investors tracking TTK Healthcare Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.
TTK Healthcare Ltd (NSE: TTKHLTCARE, BSE: 507747) is currently trading at ₹1115.40, with a market capitalization of ₹1577.02Cr. As a major player in the Health technology sector and Pharmaceuticals: major industry, TTK Healthcare Ltd remains a key stock for fundamental analysis using TTK Healthcare Ltd Ratios.
TTK Healthcare Ltd Ratios: Valuation Overview
Price to Earnings Ratio (P/E)
The TTK Healthcare Ltd P/E ratio currently stands at 20.71, making it one of the most tracked metrics in TTK Healthcare Ltd Ratios.
Historically, the TTK Healthcare Ltd P/E ratio has shown strong fluctuations:
- 2024: 20.71
- 2023: 33.35
- 2022: 2.28
- 2021: 28.17
- 2020: 15.05
The decline in TTK Healthcare Ltd P/E ratio suggests improving earnings relative to stock price.
Price to Book Ratio (P/B)
The TTK Healthcare Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 1.59.
Historical P/B trend:
- 2024: 1.59
- 2023: 2.09
- 2022: 1.53
- 2021: 3.55
TTK Healthcare Ltd shows reasonable valuation compared to its asset base.
Price to Sales Ratio (P/S)
The TTK Healthcare Ltd P/S ratio currently stands at 2.11, an important part of TTK Healthcare Ltd Ratios for revenue valuation.
Historical P/S ratio:
- 2024: 2.11
- 2023: 2.78
- 2022: 2.01
- 2021: 1.96
A stable or declining TTK Healthcare Ltd P/S ratio indicates cautious market sentiment.
TTK Healthcare Ltd Price to Cash Flow Ratio (P/CF)
The TTK Healthcare Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 29.32.
Historical TTK Healthcare Ltd Price to Cash Flow Ratio:
- 2024: 29.32
- 2023: 42.26
- 2022: 0
- 2021: 21.34
- 2020: 6.23
The declining TTK Healthcare Ltd Price to Cash Flow Ratio suggests improving cash flow strength.
TTK Healthcare Ltd Enterprise Value Ratios
Enterprise Value (EV)
The TTK Healthcare Ltd EV currently stands at ₹860Cr, representing the total company valuation including debt.
Historical EV trend:
- 2024: 860Cr
- 2023: 1273Cr
- 2022: 641Cr
- 2021: 920Cr
TTK Healthcare Ltd enterprise value consolidation suggests stable valuation.
EV/EBITDA Ratio
The TTK Healthcare Ltd EV/EBITDA ratio is currently 23.89, a key metric in TTK Healthcare Ltd Ratios to assess valuation relative to earnings.
Historical EV/EBITDA:
- 2024: 23.89
- 2023: 32.90
- 2022: 19.86
- 2021: 40.15
Stable TTK Healthcare Ltd EV/EBITDA indicates balanced valuation.
TTK Healthcare Ltd Financial Strength Ratios
Debt to Equity Ratio (D/E)
The TTK Healthcare Ltd D/E ratio is currently 0.02, reflecting leverage and financial stability.
Historical D/E:
- 2024: 0.02
- 2023: 0.02
- 2022: 0.03
- 2021: 0.07
TTK Healthcare Ltd maintains a strong balance sheet with low debt levels.
Return on Equity (ROE %)
The TTK Healthcare Ltd ROE currently stands at 7.90%, showing profitability and capital efficiency.
Historical ROE:
- 2024: 7.90
- 2023: 6.43
- 2022: 6.96
- 2021: 5.93
Declining ROE indicates pressure on profitability.
TTK Healthcare Ltd Ratios Analysis Summary
The TTK Healthcare Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether TTK Healthcare Ltd stock is undervalued, fairly valued, or overvalued.
Tracking TTK Healthcare Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.